Is PRAX or TRVI more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Trevi Therapeutics N/A -24.53% -23.37%

Does the media prefer PRAX or TRVI?

In the previous week, Praxis Precision Medicines had 8 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Praxis Precision Medicines and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Praxis Precision Medicines' score of 0.25 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRVI or IBRX?

In the previous week, ImmunityBio had 5 more articles in the media than Trevi Therapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat ImmunityBio's score of 0.05 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TRVI or QGEN?

In the previous week, Qiagen had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 3 mentions for Qiagen and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Qiagen's score of 0.43 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, NUVL or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A

Is NUVL or TRVI more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Trevi Therapeutics N/A -24.53% -23.37%

Does the media prefer NUVL or TRVI?

In the previous week, Nuvalent had 38 more articles in the media than Trevi Therapeutics. MarketBeat recorded 40 mentions for Nuvalent and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Nuvalent's score of 0.19 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 14 Very Positive mention(s) 5 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, PCVX or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$6.88 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A

Is PCVX or TRVI more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Trevi Therapeutics N/A -24.53% -23.37%

Does the media prefer PCVX or TRVI?

In the previous week, Vaxcyte had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Vaxcyte and 2 mentions for Trevi Therapeutics. Vaxcyte's average media sentiment score of 1.11 beat Trevi Therapeutics' score of 0.93 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Trevi Therapeutics (TRVI) Competitors

$13.40 -0.19 (-1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$13.20 -0.21 (-1.53%)

As of 07:19 PM Eastern

Compare

TRVI vs. PRAX, IBRX, QGEN, NUVL, and PCVX

Should you buy Trevi Therapeutics stock or one of its competitors? MarketBeat compares Trevi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trevi Therapeutics include Praxis Precision Medicines (PRAX), ImmunityBio (IBRX), Qiagen (QGEN), Nuvalent (NUVL), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, Praxis Precision Medicines had 8 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Praxis Precision Medicines and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Praxis Precision Medicines' score of 0.25 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Trevi Therapeutics' return on equity of -24.53% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Praxis Precision Medicines presently has a consensus target price of $572.72, suggesting a potential upside of 137.98%. Trevi Therapeutics has a consensus target price of $22.90, suggesting a potential upside of 70.90%. Given Praxis Precision Medicines' higher possible upside, equities research analysts clearly believe Praxis Precision Medicines is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Trevi Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	784.75	-$303.27M	-$13.37	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Summary

Trevi Therapeutics beats Praxis Precision Medicines on 8 of the 15 factors compared between the two stocks.

How does Trevi Therapeutics compare to ImmunityBio?

Trevi Therapeutics (NASDAQ:TRVI) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Trevi Therapeutics has higher earnings, but lower revenue than ImmunityBio. Trevi Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
ImmunityBio	$113.29M	64.53	-$351.40M	-$0.85	N/A

In the previous week, ImmunityBio had 5 more articles in the media than Trevi Therapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat ImmunityBio's score of 0.05 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trevi Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
ImmunityBio	-606.15%	N/A	-59.53%

Trevi Therapeutics presently has a consensus price target of $22.90, suggesting a potential upside of 70.90%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 103.44%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Comparatively, 69.5% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Trevi Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market.

Summary

Trevi Therapeutics beats ImmunityBio on 10 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Qiagen?

Trevi Therapeutics (NASDAQ:TRVI) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Qiagen has a net margin of 19.16% compared to Trevi Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Qiagen	19.16%	14.40%	8.40%

Qiagen has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Qiagen	$2.09B	3.65	$424.88M	$1.91	19.39

Trevi Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Trevi Therapeutics currently has a consensus target price of $22.90, indicating a potential upside of 70.90%. Qiagen has a consensus target price of $44.98, indicating a potential upside of 21.46%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Trevi Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

In the previous week, Qiagen had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 3 mentions for Qiagen and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Qiagen's score of 0.43 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Trevi Therapeutics and Qiagen tied by winning 8 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Nuvalent currently has a consensus target price of $131.15, suggesting a potential upside of 6.32%. Trevi Therapeutics has a consensus target price of $22.90, suggesting a potential upside of 70.90%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

In the previous week, Nuvalent had 38 more articles in the media than Trevi Therapeutics. MarketBeat recorded 40 mentions for Nuvalent and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Nuvalent's score of 0.19 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	14 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 5.0% of Nuvalent shares are held by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Trevi Therapeutics' return on equity of -24.53% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Summary

Trevi Therapeutics beats Nuvalent on 10 of the 14 factors compared between the two stocks.

How does Trevi Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

In the previous week, Vaxcyte had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Vaxcyte and 2 mentions for Trevi Therapeutics. Vaxcyte's average media sentiment score of 1.11 beat Trevi Therapeutics' score of 0.93 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Trevi Therapeutics' return on equity of -24.53% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Vaxcyte currently has a consensus price target of $86.00, indicating a potential upside of 89.34%. Trevi Therapeutics has a consensus price target of $22.90, indicating a potential upside of 70.90%. Given Vaxcyte's higher possible upside, equities analysts plainly believe Vaxcyte is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Vaxcyte has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Summary

Trevi Therapeutics beats Vaxcyte on 8 of the 14 factors compared between the two stocks.

Get Trevi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVI vs. The Competition

Export

Metric	Trevi Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.90B	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-41.88	18.99	24.46	23.62
Price / Sales	N/A	290.48	500.50	105.27
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	9.37	8.00	10.43	6.70
Net Income	-$42.76M	$23.89M	$3.56B	$337.26M
7 Day Performance	-0.37%	-3.49%	-1.39%	-1.41%
1 Month Performance	-7.59%	1.03%	0.86%	1.15%
1 Year Performance	105.84%	34.39%	19.42%	22.61%

Trevi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVI Trevi Therapeutics	2.6221 of 5 stars	$13.40 -1.4%	$22.90 +70.9%	+112.0%	$1.90B	N/A	N/A	20
PRAX Praxis Precision Medicines	2.7474 of 5 stars	$272.00 +5.4%	$572.72 +110.6%	+462.4%	$7.58B	$8.55M	N/A	110
IBRX ImmunityBio	2.9961 of 5 stars	$7.10 -1.8%	$14.20 +100.0%	+110.8%	$7.44B	$113.29M	N/A	590
QGEN Qiagen	4.6028 of 5 stars	$35.91 +0.6%	$44.98 +25.3%	-22.3%	$7.40B	$2.09B	18.75	5,654	Short Interest Decrease
NUVL Nuvalent	1.8739 of 5 stars	$91.72 +0.4%	$141.24 +54.0%	+62.0%	$7.25B	N/A	N/A	40	Trending News Analyst Downgrade Insider Trade Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVI) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevi Therapeutics (TRVI) Competitors

TRVI vs. PRAX, IBRX, QGEN, NUVL, and PCVX

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Summary

How does Trevi Therapeutics compare to ImmunityBio?

Summary

How does Trevi Therapeutics compare to Qiagen?

Summary

How does Trevi Therapeutics compare to Nuvalent?

Summary

How does Trevi Therapeutics compare to Vaxcyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevi Therapeutics (TRVI) Competitors

TRVI vs. PRAX, IBRX, QGEN, NUVL, and PCVX

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Does the media prefer PRAX or TRVI?

Which has more risk and volatility, PRAX or TRVI?

Is PRAX or TRVI more profitable?

Do analysts prefer PRAX or TRVI?

Do institutionals & insiders have more ownership in PRAX or TRVI?

Which has higher earnings & valuation, PRAX or TRVI?

Summary

How does Trevi Therapeutics compare to ImmunityBio?

Which has stronger valuation and earnings, TRVI or IBRX?

Does the media favor TRVI or IBRX?

Is TRVI or IBRX more profitable?

Do analysts recommend TRVI or IBRX?

Do institutionals and insiders hold more shares of TRVI or IBRX?

Which has more volatility & risk, TRVI or IBRX?

Summary

How does Trevi Therapeutics compare to Qiagen?

Is TRVI or QGEN more profitable?

Which has higher valuation and earnings, TRVI or QGEN?

Which has more risk & volatility, TRVI or QGEN?

Do analysts prefer TRVI or QGEN?

Does the media refer more to TRVI or QGEN?

Do insiders and institutionals hold more shares of TRVI or QGEN?

Summary

How does Trevi Therapeutics compare to Nuvalent?

Do analysts recommend NUVL or TRVI?

Which has preferable earnings & valuation, NUVL or TRVI?

Does the media prefer NUVL or TRVI?

Do institutionals & insiders have more ownership in NUVL or TRVI?

Which has more volatility and risk, NUVL or TRVI?

Is NUVL or TRVI more profitable?

Summary

How does Trevi Therapeutics compare to Vaxcyte?

Which has preferable valuation and earnings, PCVX or TRVI?

Does the media prefer PCVX or TRVI?

Do insiders & institutionals hold more shares of PCVX or TRVI?

Is PCVX or TRVI more profitable?

Do analysts prefer PCVX or TRVI?

Which has more volatility and risk, PCVX or TRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools